贝利尤单抗与阿尼鲁单抗治疗系统性红斑狼疮的疗效与安全性:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入11项随机对照试验(n=8607),比较贝利尤单抗与阿尼鲁单抗联合标准治疗对成人SLE的疗效与安全性。两种生物制剂SRI-4应答均优于安慰剂且无显著差异;阿尼鲁单抗BICLA应答优于贝利尤单抗,但带状疱疹风险更高。
要点
- 阿尼鲁单抗与贝利尤单抗SRI-4应答均优于安慰剂,两者间无显著差异
- 阿尼鲁单抗BICLA应答优于贝利尤单抗(OR 1.56),但证据为间接且确定性中等
- 阿尼鲁单抗带状疱疹风险显著高于贝利尤单抗(OR 4.74),SAEs与严重感染相似
核心结论
- 阿尼鲁单抗与贝利尤单抗SRI-4应答相似,阿尼鲁单抗BICLA应答更高但需谨慎解读。
- 临床应个体化选择生物制剂,权衡BICLA获益与阿尼鲁单抗更高的带状疱疹风险。
研究设计与样本
- 系统综述与网状Meta分析,纳入11项随机对照试验(n=8607),其中阿尼鲁单抗4项、贝利尤单抗7项(含2项仅安全性试验)。
- 比较贝利尤单抗或阿尼鲁单抗联合标准治疗与安慰剂联合标准治疗,采用RoB 2评估偏倚风险、GRADE/CINeMA框架评估证据确定性。
主要发现
- SRI-4应答:阿尼鲁单抗OR 1.78(95%CI 1.41-2.24),贝利尤单抗OR 1.62(95%CI 1.38-1.90),两者间无显著差异。
- BICLA应答:阿尼鲁单抗优于贝利尤单抗(OR 1.56,95%CI 1.10-2.21)。
- 黏膜皮肤和肌肉骨骼应答两种生物制剂均优于安慰剂,肾脏和心血管/呼吸结局无统计学显著差异。
- 安全性:两种生物制剂SAEs和严重感染相似,阿尼鲁单抗带状疱疹风险高于贝利尤单抗(OR 4.74,95%CI 2.00-11.21)。
关键数值与推荐
- SRI-4应答OR:阿尼鲁单抗1.78(95%CI 1.41-2.24),贝利尤单抗1.62(95%CI 1.38-1.90)。
- BICLA应答阿尼鲁单抗对比贝利尤单抗OR 1.56(95%CI 1.10-2.21)。
- 带状疱疹阿尼鲁单抗对比贝利尤单抗OR 4.74(95%CI 2.00-11.21)。
临床怎么用
- 活动性SLE患者选择生物制剂时可参考SRI-4应答相似性,结合BICLA获益与带状疱疹风险个体化决策。
- 对带状疱疹风险较高的患者,贝利尤单抗可能较阿尼鲁单抗更为适宜。
局限性
- 贝利尤单抗BICLA数据来自事后分析。
- 阿尼鲁单抗BICLA优于贝利尤单抗的结论依赖间接证据,证据确定性中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the efficacy and safety of belimumab and anifrolumab in adult patients with SLE. METHODS: We conducted a systematic review and network meta-analysis (NMA) of randomized controlled trials (RCTs) in SLE. We included RCTs comparing belimumab or anifrolumab plus standard of care versus placebo plus standard of care. Outcomes included SRI-4, BICLA, selected BILAG organ-domain responses, and safety endpoints; belimumab BICLA data were derived from post hoc analyses. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. Risk of bias was assessed with RoB 2; certainty in network estimates was evaluated using the GRADE approach as applied in the CINeMA framework. RESULTS: Eleven trials (n = 8607) were included (4 anifrolumab; 7 belimumab, including 2 safety-only trials). Both biologics were associated with higher odds of achieving an SRI-4 response than placebo: anifrolumab OR 1.78 (95% CI 1.41-2.24); belimumab OR 1.62 (95% CI 1.38-1.90), with no significant difference between active treatments. For BICLA, anifrolumab was superior to belimumab (OR 1.56, 95% CI 1.10-2.21). Mucocutaneous and musculoskeletal responses favored both biologics versus placebo, whereas renal and cardiovascular/respiratory effects were not statistically significantly different. In safety analyses, SAEs and serious infections were similar between biologics, whereas herpes zoster was higher with anifrolumab versus belimumab (OR 4.74, 95% CI 2.00-11.21). CONCLUSION: In this NMA, anifrolumab and belimumab achieved similar SRI-4 responses. Anifrolumab showed a higher BICLA response than belimumab, but this finding should be interpreted cautiously given reliance on indirect evidence and moderate certainty. Clinically, these data support individualized biologic selection, weighing potential benefit on BICLA against the consistently higher herpes zoster risk with anifrolumab.
引用
- Martinez-Martinez MU, Tejada-Llacsa PJ, Prokop LJ, et al. Efficacy and safety of belimumab and anifrolumab in systemic lupus erythematosus: A systematic review and network meta-analysis. Semin Arthritis Rheum. 2026. PMID: 42308962. doi:10.1016/j.semarthrit.2026.153022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。